Genentech 8-K Results of Operations and Financial Condition

EXHIBIT 99.2

GENENTECH, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In millions, except per share amounts)

(Unaudited)

	Three Months
	Ended March 31,
	2008			2007
Revenues:
Product sales	$	2,379		$	2,329
Royalties		616			419
Contract revenue		68			95
Total operating revenues		3,063			2,843
Costs and expenses:
Cost of sales (includes employee stock-based compensation expense: three months–2008–$22; 2007–$16)		389			392
Research and development (includes employee stock-based compensation expense: three months–2008–$42; 2007–$38)		617			610
Marketing, general and administrative (includes employee stock-based compensation expense: three months–2008 and 2007–$46)		517			491
Collaboration profit sharing		279			252
Recurring charges related to redemption and acquisition		43			26
Special items: litigation-related		14			13
Total costs and expenses		1,859			1,784
Operating income		1,204			1,059
Other income (expense):
Interest and other income, net(1)		74			74
Interest expense		(18	)		(18	)
Total other income, net		56			56
Income before taxes		1,260			1,115
Income tax provision		470			409
Net income	$	790		$	706
Earnings per share:
Basic	$	0.75		$	0.67
Diluted	$	0.74		$	0.66
Weighted average shares used to compute earnings per share:
Basic		1,053			1,053
Diluted		1,068			1,071

_________________________

(1) “Interest and other income, net” includes interest income, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain debt and biotechnology equity securities.  For further detail, refer to our web site at www.gene.com.

GENENTECH, INC.

SELECTED CONSOLIDATED FINANCIAL DATA

(In millions)

(Unaudited)

	March 31,		December 31,
	2008		2007
Selected consolidated balance sheet data:
Cash, cash equivalents and short-term investments	$	4,857	$	3,975
Accounts receivable – product sales, net		889		847
Accounts receivable – royalties, net		701		620
Accounts receivable – other, net		228		299
Inventories		1,469		1,493
Long-term marketable debt and equity securities		2,201		2,090
Property, plant and equipment, net		5,135		4,986
Goodwill		1,577		1,577
Other intangible assets		1,127		1,168
Other long-term assets		378		366
Total assets		20,118		18,940
Total current liabilities		3,972		3,918
Long-term debt(1)		2,460		2,402
Total liabilities		7,204		7,035
Total stockholders’ equity		12,914		11,905

	Three Months
	Ended March 31,
	2008		2007
Selected consolidated cash flow data:
Capital expenditures(1)	$	200	$	209
Total depreciation and amortization expense		139		106

_________________________

(1) Capital expenditures exclude approximately $42 million at March 31, 2008 and $57 million at March 31, 2007 in capitalized costs related to our accounting for construction projects for which we are considered to be the owner during the construction period.  We have recognized related amounts as a construction financing obligation in long-term debt.  The balances in long-term debt related to the construction financing obligation are $440 million at March 31, 2008 and $399 million at December 31, 2007.